David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in combination with Zepbound helped prevent muscle loss.

Scholar Rock shares launched 362% to 34.28. That put shares at their highest point since November 2021. The news also buoyed shares of Biohaven, which is working on a similar treatment option for ...

Scholar Rock also granted the underwriters of the offering a 30-day option to purchase up to an additional 1,861,314 shares of common stock at the offering price. For perspective, ...

Scholar Rock Holding Corp.'s stock soared more than 315% Monday to put it on track for its biggest ever one-day gain, after the clinical-stage biotech company said a late-stage trial of a ...

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.

Scholar Rock announced the company will present new data at the 2022 FASEB Science Research Conference (SRC), taking place between July 17–21, 2022.

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases ...

CAMBRIDGE, Mass., February 25, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

Scholar Rock, a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy and other severe and debilitating neuromuscular ...

Scholar Rock Holding focuses on the discovery of drugs for treating illnesses, in which signaling by protein growth factors is important. SRRK tested a total of 58 patients in Phase 2.